Integra LifeSciences Holdings (IART) 2023年年度报告「NASDAQ」.pdf

《Integra LifeSciences Holdings (IART) 2023年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Integra LifeSciences Holdings (IART) 2023年年度报告「NASDAQ」.pdf（244页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2023 orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 193

2、4For the transition period from to COMMISSION FILE NO.000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)Delaware 51-0317849(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)(I.R.S.EMPLOYER IDENTIFICATION NO.)1100 Campus Road 08540Pri

3、nceton,New Jersey(ZIP CODE)(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)REGISTRANTS TELEPHONE NUMBER,INCLUDING AREA CODE:(609)275-0500SECURITIES REGISTERED PURSUANT TO SECTION 12(b)OF THE ACT:Title of Each ClassTrading SymbolName of Exchange on Which RegisteredCommon Stock,Par Value$.01 Per ShareIARTNasd

4、aq Global Select MarketSECURITIES REGISTERED PURSUANT TO SECTION 12(g)OF THE ACT:NONEIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Secti

5、on 13 or 15(d)of the Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that theregistrant was required to file such reports),and

6、(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding12 months(or